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Abstract 25 
 26 
Probiotic bacteria have gained popularity as a defence against disorders of the bowel. 27 
However, the acid sensitivity of these cells results in a loss of viability during gastric passage 28 
and, consequently, a loss of efficacy. Probiotic treatment can be supplemented using 29 
‘prebiotics’, which are carbohydrates fermented specifically by probiotic cells in the body. This 30 
combination of probiotic and prebiotic is termed a ‘synbiotic’. Within this article a 31 
multiparticulate dosage form has been developed, consisting of poly(D,L-lactic-co-glycolic acid) 32 
(PLGA) microcapsules containing prebiotic Bimuno™ incorporated into an alginate-chitosan 33 
matrix containing probiotic Bifidobacterium breve.  The aim of this multiparticulate was that, 34 
in vivo, the probiotic would be protected against gastric acid and the release of the prebiotic 35 
would occur in the distal colon. After microscopic investigation, this synbiotic multiparticulate 36 
was shown to control the release of the prebiotic during in vitro gastrointestinal transit, with 37 
the release of galacto-oligosaccharides (GOS) initially occurred over 6 h, but with a triphasic 38 
release pattern giving further release over 288 h. Encapsulation of B.breve in multiparticulates 39 
resulted in a survival of 8.0 ± 0.3 log CFU/mL cells in acid, an improvement over alginate-40 
chitosan microencapsulation of 1.4 log CFU/mL. This was attributed to increased 41 
hydrophobicity by the incorporation of PLGA particles. 42 
 43 
 44 
 45 
Abbreviations: DCM, dichloromethane; FITC, fluorescein isothiocyanate; GI, gastrointestinal; 46 
GOS, galacto-oligosaccharides; IL-6, interleukin-6; PBS, phosphate-buffered saline; 47 
polydispersity index, PDI; PLGA, poly(D,L-lactic-co-glycolic acid); TNF-α, tumor necrosis factor 48 
α; WC, Wilkins-Chalgren 49 
3 
 
1.0 Introduction 50 
  51 
Probiotic bacteria have attracted interest due to their potential to alleviate some specific 52 
conditions of the bowel when administered orally (Rembacken et al., 1999). The intention of 53 
taking these cells orally is to modify the balance of the indigenous gut microflora in favour of 54 
strains which can exert some positive biological action (Fuller, 1991). These biological actions 55 
are numerous, and sometimes poorly understood. Examples of probiotic action include: the 56 
modulation of immune response, competition with pathogens and the production of 57 
antimicrobial compounds (Ng et al., 2009). Research suggests that these cells are most 58 
effective whilst live (or ‘viable’), and passage through the stomach often results in cell death, 59 
lowering the efficacy of an administration. Thus, research has focused on methods to improve 60 
cell survival in the stomach, and, as a result, improve the efficacy of a probiotic (Cook et al., 61 
2012). Commonly, microencapsulation, which involves the entrapment of the probiotic cells 62 
into polymeric materials, is used to achieve this aim. Research has traditionally focussed on 63 
the use of polysaccharides, such alginate (Chavarri et al., 2010; Cook et al., 2011; Cook et al., 64 
2013; Mokarram et al., 2009), xanthan gum (Ding and Shah, 2009) and starch 65 
(Muthukumarasamy et al., 2006; Sultana et al., 2000), but there is an emerging trend towards 66 
the use of encapsulation in proteins, such as casein (Heidebach et al., 2009; Oliveira et al., 67 
2007), whey protein (Doherty et al., 2012a; Doherty et al., 2012b; Doherty et al., 2010, 2011) 68 
and gelatin (Borza et al., 2010; Li et al., 2009). 69 
 An alternative approach to boost the number of probiotic cells in the intestine is by the 70 
consumption of a ‘prebiotic’. These prebiotics are compounds which are specifically fermented 71 
by a probiotic in vivo, increasing the number of these cells present in the host (Gibson et al., 72 
2004; Gibson and Roberfroid, 1995). One such prebiotic is BiMuno™, which is comprised of 73 
mostly galacto-oligosaccharides (GOS) with degrees of polymerisation (DP) of 2-4, having β 1–74 
3, β 1–4, and β 1–6 linkages, and a disaccharide fraction of α 1–6 galactobiose (Tzortzis et al., 75 
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2005). BiMuno™ has been shown to reduce colonisation of pathogenic Salmonella 76 
Typhimurium in mice by Searle et al (Searle et al., 2009).The functional components of the 77 
BiMuno™ mixture are the GOS which are believed not only to stimulate the growth of 78 
probiotic bacteria, but may also be able to interact directly with the subject’s immune system. 79 
This latter possibility has been touted due to studies in murine BALB/c macrophage models 80 
showing up-regulation of cytokines related to immune response, specifically TNF-α and IL-6 81 
(Searle et al., 2012). It has been shown by Tzorzis et al (Tzortzis et al., 2005) that BiMuno™ had 82 
a bifidogenic effect in the colon of pigs, boosting number of Bifidobacterium spp by 0.74 83 
log(CFU)/mL in the proximal colon, but by only 0.38 log(CFU)/mL in the distal regions of the 84 
colon. It was postulated that this imbalance in growth may be caused by the fermentation of 85 
GOS by cells in the proximal region, reducing the concentration of the usable GOS further 86 
along the gut. A product containing both a pro- and pre- biotic is termed a ‘synbiotic’, and has 87 
been highlighted as a possible means of improving the efficacy of a probiotic supplement. It 88 
was the intention of the work herein to produce a microencapsulated synbiotic product 89 
containing GOS and a probiotic (Bifidobacterium breve), to impart protection to the 90 
encapsulated cells and to control the release of the prebiotic across the intestine, which can 91 
then act on the hosts indigenous microflora. 92 
The production of an encapsulated synbiotic has several different challenges compared to the 93 
formulation of the probiotic alone. One particular advantage of encapsulating GOS, compared 94 
to probiotic cells, is that relatively harsh processing conditions during the encapsulation step 95 
may be used. However, for a synbiotic containing GOS and probiotic cells, careful 96 
consideration must be taken in order to ensure the applicability of the system to both 97 
bioactives. In order to improve the survival of cells through the stomach, probiotics have been 98 
microencapsulated into alginate polysaccharide gels, which have been modified by various 99 
methods (Chandramouli et al., 2004; Chavarri et al., 2010; Cook et al., 2012; Cui et al., 2007; 100 
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Graff et al., 2008). It has been shown that coating alginate microcapsules with one or more 101 
layers of chitosan leads to an improvement in the survival of probiotic cells during exposure to 102 
acid (Chavarri et al., 2010; Cook et al., 2011; Doherty et al., 2012a; Liserre et al., 2007). It has 103 
also been demonstrated that the incorporation of other materials, such as starch, into the 104 
alginate matrix can affect the microcapsule properties (Homayouni et al., 2008; Sultana et al., 105 
2000). In this paper, a multiparticulate microencapsulation system was devised to offer 106 
controlled release to GOS, and protection of B. breve to acid. This consisted of individually 107 
microencapsulated BiMuno™, which was then incorporated into a chitosan-coated alginate gel 108 
containing B. breve, a model probiotic strain. The GOS was encapsulated into a separate 109 
system which offers a time-dependent release of small molecules, as the alginate 110 
microencapsulation system is too porous to contain the GOS contained in BiMuno™.  111 
Poly(D,L-Lactic-co-Glycolic acid) (PLGA) was identified as a plausible material for the time-112 
dependent release of GOS. PLGA was chosen as an encapsulating material as it is highly 113 
biocompatible, FDA-approved, and has been shown to control the release of water-soluble 114 
drugs, extending their delivery from hours (Wischke and Schwendeman, 2008) up to months 115 
(Corrigan and Li, 2009). The biodegradation process occurs simply in solution by hydrolysis of 116 
the ester linkages between the monomers. This results in the breakdown of the polymer 117 
chains into lactic and glycolic acid, both of which are easily metabolised in the body.  118 
There have been a number of multiparticulate dosage forms reported in the literature for the 119 
targeting of drugs to the intestine. Eudragit-coated PLGA particles containing budesonide have 120 
been fabricated by Krishnamachari et al (Krishnamachari et al., 2007). These particles were 121 
intended to deliver the encapsulated drug to the colon, and showed impressive steady release 122 
of drug over 25 hours. There has also been a study of alginate-PLGA multiparticulates for the 123 
delivery of silymarin (El-Sherbiny et al., 2011). These delivery devices consisted of PLGA 124 
nanoparticles, produced through a single emulsion solvent evaporation technique, which were 125 
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incorporated into alginate matrices through the conventional ionotropic gelation method. In 126 
vitro GI release studies found that approximately 80 % of encapsulated silymarin was delivered 127 
over around 10 hours. The release was pH dependent, with a clear targeting of delivery to 128 
simulated intestinal solution. After the change of pH there was a release of up to 50 % of 129 
silymarin over the course of 2 hours. 130 
 It should be noted that diarrhoea is common in bowel disorders, which may lead to 131 
premature clearing of microparticles. It has been found that clearing due to diarrhoea is size-132 
dependent and that particles of less than 200 microns are retained more effectively during 133 
diarrhoea, thus, it is important that microparticles are produced with diameters lower than 134 
this threshold (Lamprecht et al., 2004). 135 
This work aimed to develop a multiparticulate system to encapsulate a synbiotic combination 136 
of GOS and B.breve. The development of PLGA-GOS microcapsules will be discussed, followed 137 
by characterisation of particle size and morphology using microscopy. The release of GOS from 138 
these particles in simulated GI conditions was then evaluated and the system expanded to a 139 
multiparticulate containing probiotic cells, with associated cell and GOS release data.  140 
2.0 Materials and methods 141 
2.1 Materials 142 
 143 
Sodium alginate (19-40 kDa, M:G ratio 3.3 ± 0.3 (Wright et al., 2012)), low molecular-weight 144 
chitosan (103 kDa, degree of deacetylation: 85.6 %) and fluorescein isothiocyanate (FITC) were 145 
purchased from Sigma-Aldrich (Gillingham, U.K.). Bifidobacterium breve NCIMB 8807 was 146 
purchased from the National Collection of Industrial Food and Marine Bacteria (Aberdeen, 147 
U.K.). Wilkins-Chalgren (WC) anaerobe agar and phosphate-buffered saline (PBS) were 148 
purchased from Oxoid (UK). PLGA 5002A was purchased from PURAC (Gorinchem, 149 
Netherlands). This grade of PLGA was chosen as it had a relatively quick time for complete 150 
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biodegradation, 0.5-1 month(s). The manufacturer’s guide gave an Mw of 17 kDa. 151 
Dichloromethane (DCM) was purchased from Sigma-Aldrich (U.K.). BiMuno™ was provided by 152 
Clasado Research Services Ltd (Reading, U.K.) as a 68 % (w/v) aqueous syrup. Simulated 153 
gastrointestinal (GI) solutions were made according to the United States Pharmacopeia, 154 
without enzymes. Adjustments to pH are shown in brackets after solution name. Chitosan 155 
solutions were at 0.4 % w/v in 0.1 M acetic acid and the pH adjusted to pH 6.0 with 1 M NaOH. 156 
2.2 Production of PLGA microcapsules containing GOS 157 
The microencapsulation of GOS was attempted by a solvent evaporation technique (Herrmann 158 
and Bodmeier, 1995). To form the WOW emulsion, 0.5 mL aqueous BiMuno™ solution of a 159 
known concentration was added to 10 mL PLGA solution (10 % w/v) in DCM with overhead 160 
stirring at 1200 rpm for 60 s. This primary emulsion was then transferred into 100 mL aqueous 161 
alginate solution (1 % w/v) with overhead stirring at 1200 rpm, resulting in the formation of a 162 
secondary WOW emulsion. The WOW emulsion was then left to stir at room temperature for 163 
60 min which allowed the evaporation of DCM. After 60 min of stirring, microcapsules were 164 
collected via centrifugation at 1,000 rpm for 10 min, twice washed with 50 mL deionised water 165 
and freeze-dried (Thermo LL3000) to allow removal of water from the discrete phase. Samples 166 
were then stored in a desiccator before use. Scanning electron microscopy (SEM) was 167 
performed on the samples to examine their structure. The initial experiment conducted was 168 
simply to establish the relationship between particle size and the concentration of BiMuno™ 169 
used. BiMuno™ solutions of 10, 20 and 30 % (w/v) were prepared and used as the internal 170 
water phase in the procedure above. The particles produced were then sized by observation 171 
on a light microscope (Leica DM2500). The diameter of 100 particles was measured using 172 
ImageJ.  173 
 174 
2.3.0 Release of GOS from PLGA microcapsule in in vitro GI solutions 175 
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2.3.1 Ion-exchange HPLC of BiMuno™ 176 
BiMuno’s GOS components were analysed by ion-exchange HPLC. In order to quantify GOS in 177 
the following release experiments, a Rezex RCM-monosaccharide column (Phenomenex, U.K.) 178 
was used, running HPLC-grade water at a flow rate of 0.5 mL/min with an oven temperature of 179 
85 °C (Fig 1s, Supporting information). However, this HPLC technique was very sensitive to 180 
salts, especially phosphates, present in the GI solutions. The salts were removed from solution 181 
using an amino-column running 60 % v/v acetonitrile in water at a flow rate of 1 mL/min with 182 
an oven temperature of 30 °C. The GOS peak could then be separated from phosphate salts 183 
using a fraction collector and the solvent removed from solution by heating in an oil bath (50 184 
°C, until complete evaporation). The resulting residue was dissolved in a volume of pure water 185 
equal to that injected (200 µL) and was analysed once more by the ion-exchange method. This 186 
method led to a significant (52.9 ± 2.6 %), but reproducible loss of GOS, which could be 187 
corrected for during determination of GOS concentration in simulated GI solutions. It should 188 
also be clarified that when describing the data from these release experiments the GOS 189 
concentration is given as a percentage of the theoretical maximum GOS content assuming 100 190 
% encapsulation efficiency.  191 
 192 
2.3.2 Quantification of GOS release in simulated GI solutions 193 
GOS-containing PLGA microcapsules were produced as above and re-suspended in 10 mL 194 
simulated gastric solution (at pH 2.0). This solution was then incubated at 37 °C with shaking at 195 
100 rpm for 60 min. A sample was then taken through a syringe and microfilter to ensure that 196 
no microcapsules were drawn into the syringe. The particles in solution were then centrifuged 197 
at 1,000 rpm for 10 min, the simulated gastric solution removed and the particles re-198 
suspended in 50 mL simulated intestinal solution (pH 6.0) to simulate entry to the small 199 
intestine, and incubated as before. After 60 min of incubation a sample was taken and the 200 
particles in solution centrifuged, the supernatant removed and the resulting pellet re-201 
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suspended in 50 mL simulated intestinal solution (pH 7.2) to simulate the pH of the distal small 202 
intestine, and incubated. After 120 min at this pH a sample was taken. This two stage process 203 
was attempting to approximate the pH, temperature and duration of small intestinal passage, 204 
following gastric passage. The microcapsules were then removed from solution by 205 
centrifugation and re-suspended in 50 mL simulated intestinal solution (pH 5.5), which 206 
intended to simulate the pH of the proximal colon. Samples (2 mL) were then taken at 207 
numerous time points for up to 12 days. After each sample was taken, an equivalent volume 208 
of simulated GI solution (2 mL) was added to replace that loss. An overview of this simulated 209 
GI passage is shown in the supplementary information (Fig. 2s).  210 
 211 
2.4 Effect of discrete aqueous phase volume on release rate of GOS from PLGA microcapsules 212 
 213 
PLGA microcapsules containing GOS were prepared as before, but with 0.5, 1.0 and 2.0 mL 214 
BiMuno™ solution (20 % w/v) added during the formation of the primary emulsion. These 215 
microcapsules were then put through the simulated GI passage described previously. The 216 
encapsulation efficiency of the 1.0 mL internal phase microcapsules was estimated by the 217 
measurement of GOS in the continuous alginate phase. 218 
 219 
2.5.0 Release of GOS from alginate and alginate-chitosan microcapsules 220 
In order to evaluate the effect of alginate microencapsulation on the release of GOS, an in 221 
vitro GI passage was used. A solution containing 2 % w/v BiMuno™ and 2 % w/v alginate was 222 
prepared. 1 mL of this solution was extruded with a syringe and pump (2 mL/min) into 50 mL 223 
CaCl2 solution (0.05 M) and left to harden for 30 min. Then, in the case of chitosan-coated 224 
capsules, the hardened sample was placed into chitosan solution for 10 min to allow coating of 225 
the samples. The capsules were then dried by fluid-bed drying for 15 min at 30°C, with an 226 
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airflow at 50 % power. To evaluate the release of GOS from these particles, the in vitro GI 227 
passage previously described was used. However, the study was halted before the final section 228 
(pH 5.5) due to the complete dissolution of the microcapsules. 229 
 230 
2.5.1 Purification of GOS samples revisited 231 
Due to the incompatibility of alginate with the eluent in the purification procedure used 232 
previously, a new purification procedure was used for the experiments involving alginate. 233 
Samples (10 mL) were adjusted to pH 7-7.5, with a measured volume of NaOH (1 M). To these 234 
samples 10 mL CaCl2 (0.05 M) was added, at which point the solutions became cloudy due to 235 
the formation of insoluble calcium phosphate and calcium-alginate. The solution could then be 236 
microfiltered (0.45 μm filter), removing the phosphates and alginate present. These samples 237 
could then be analysed by ion-exchange HPLC. This method was validated before use by the 238 
purification of a known concentration of BiMuno™, giving full recovery of GOS. 239 
 240 
2.6 Release of GOS from alginate and alginate-chitosan encapsulated PLGA multiparticulates 241 
The previously evaluated GOS/PLGA microcapsules were prepared as before and placed into 242 
10 mL alginate solution (2 % w/v) with stirring before extrusion into 500 mL CaCl2 solution 243 
(0.05 M) with a syringe and pump (2 mL/min). These multiparticulate capsules were allowed to 244 
harden for 30 min and, in the case of chitosan-coated capsules, placed in 0.4 % w/v chitosan 245 
solution for 10 min. The capsules were then dried by fluid-bed drying as before. Fluid-bed 246 
dried microcapsules were stored in a desiccator until use. These multiparticulates were then 247 
run through the same in vitro GI transit model used for the GOS/PLGA microcapsules, 248 
shortened to 72 h, due to the likelihood of excretion in vivo by this point. Additionally, due to 249 
the larger sample size, volumes of simulated GI solutions used were multiplied ten-fold. 250 
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Samples (10 mL) were collected as previously described and taken for purification before 251 
analysis. 252 
 253 
2.7 Viability and release of B. breve encapsulated in synbiotic microcapsules 254 
To determine whether the final prebiotic system would also allow the survival of cells, an in 255 
vitro test was conducted. B. breve was grown at 37 ˚C for 72 h, anaerobically on WC anaerobe 256 
agar before inoculation into 10 mL TPY broth. The inoculated cell suspension was grown at 37 257 
˚C for 22 h, before centrifugation at 3200 rpm for 15 min at 4 ˚C. The supernatant was 258 
removed and the cell pellet re-suspended in sufficient 2 % w/v microfiltered alginate solution 259 
to OD600 ~2.0. To 10 mL of this polymer/cell solution, PLGA microcapsules containing GOS were 260 
added, produced with 1 mL internal phase as previously described, with stirring. This solution 261 
was extruded using a syringe and pump (flow rate 2.0 mL/min) into 50 mL CaCl2 (0.05 M) and 262 
left in solution to harden for 30 min. Microcapsules were then coated with 1 layer of chitosan 263 
as described in a previous publication (Doherty et al., 2012a). These synbiotic multiparticulates 264 
were then dried by fluid-bed drying for 15 min at 30 ˚C, and airflow at 50 % of full power. The 265 
microcapsules were then put through the simulated GI transit described previously. Samples 266 
taken were assessed for live cell content by plate counts on WC agar. This gave a 267 
representation of the numbers of cells surviving in the low pH gastric solution and the rate of 268 
release of these cells. 269 
 270 
2.8 Scanning electron microscopy 271 
SEM was performed on samples throughout various stages of this article. Typically, samples 272 
were prepared for SEM by drying, followed by adhesion to a carbon stub and sputter coating 273 
with gold. SEM was performed on an FEI Quanta 600 FEG environmental SEM under high-274 
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vacuum and using a point size of 3. The images presented in Fig.1 used a 5.0 kV electron beam, 275 
all other images were taken using a 20 kV electron beam. 276 
 277 
2.9 Statistical analysis 278 
Where used, statistical significance was determined by one-way ANOVA with Tukey’s post-hoc 279 
test using Graphpad Prism (USA). 280 
 281 
3.0 Results and discussion 282 
3.1 Production and sizing of PLGA microcapsules 283 
The production of PLGA microcapsules containing GOS was achieved using a solvent 284 
evaporation technique based on the modification of known methods (Herrmann and 285 
Bodmeier, 1995). Observation of these microcapsules using SEM revealed that the 286 
microcapsules were spherical with a smooth surface (Figure 1). The sample appears relatively 287 
polydisperse, and any damaged capsules showed that the microcapsules were hollow with a 288 
dense crust with a thickness of approximately 1 μm (measured by ImageJ).  289 
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 290 
Figure 1: SEM images of PLGA microcapsules containing GOS. Please note that the damage 291 
seen on the right image is atypical for this sample, and was chosen to demonstrate that the 292 
capsules were hollow. 293 
 294 
The effect of BiMuno™ concentration on the average particle size and distribution was 295 
determined by light microscopy and subsequent image analysis using ImageJ. This data, shown 296 
in Table 1, is represented as the mean diameter and polydispersity index (PDI) of three 297 
separate batches of microcapsules. The PDI is defined as: 298 
PDI = (standard deviation/mean)2 299 
It is clear from this experiment that increasing the concentration of BiMuno™ from 10 to 20 % 300 
(w/v) resulted in a greater than two-fold decrease in the particle diameter. Increasing the 301 
concentration to 30 % (w/v) did not have a significant effect on the particle diameter. There 302 
was no significant difference in the polydispersity of the particles between conditions. The 303 
polydispersity of the sample could have consequences on the release rate of GOS from these 304 
particles. The release rate should be dependent in part on the size of the microcapsules (Klose 305 
et al., 2006), so it is important to attempt to make the particle size as regular as possible. As 306 
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there was no difference between the 20 and 30 % GOS samples, 20 % GOS was taken on for 307 
further experimentation. It should be noted that the concentration of GOS in the internal 308 
phase may affect the encapsulation efficiency of the system (Mao et al, 2007), and may be a 309 
factor which could be optimised in terms of encapsulation efficiency, as well as particle size. 310 
Table 1: Effect of GOS concentration on PLGA particle size and PDI. Data given as mean ± 311 
standard deviation (n=3). Superscript letters separate values which are significantly different 312 
(p<0.05).  313 
BiMuno™ in internal 
phase (%) 
Particle diameter (μm) PDI 
10 97.3 ± 9.1a 0.6 ± 0.1c 
20 45.2 ± 5.3b 0.4 ± 0.1c 
30 44.8 ± 3.7b 0.5 ± 0.1c 
 314 
3.2 Release of GOS from PLGA microcapsules during exposure to simulated GI solutions  315 
 316 
The release of GOS from these GOS/PLGA microcapsules under in vitro GI conditions was 317 
measured by ion-exchange HPLC. These studies were initially conducted over a lengthy time 318 
period, to understand the full release profile of PLGA microcapsules containing GOS. 12 days 319 
incubation in simulated intestinal solution gave a triphasic release profile (Figure 2). The initial 320 
phase of release (0-6 h) was likely caused by the diffusion of GOS through pores or the 321 
polymer itself. This was followed by a second phase of very little release (6-24 h) at which 322 
point the GOS able to diffuse had diminished and the PLGA chains were slowly hydrolysing. 323 
The third phase of release (24-288 h) was the result of the erosion of the particles as the 324 
molecular weight of PLGA reduced to such a degree that it became water-soluble. This 325 
triphasic release profile predicts that around 25 % of GOS (19 mg GOS/g particles) should be 326 
released after 6 h intestinal transit. This transit time should cover gastric and small intestinal 327 
transit (approximately 4.5 h) and the beginnings of large intestinal passage.  The second phase 328 
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of release should occur during the remainder of large intestinal transit, however, very little 329 
GOS release occurs during this time. The third phase of release would not be reached in the 330 
body unless the PLGA particles were very effectively retained after accumulation in ulcers, as 331 
has been reported for PLGA microcapsules (Schmidt et al., 2013). This triphasic release profile 332 
has been reported by other groups working on hollow PLGA particles (Cohen et al., 1991; 333 
Sturesson et al., 1993). 334 
 335 
 336 
Figure 2: Release of GOS from PLGA microparticles, expressed as a percentage of GOS initially 337 
added to emulsion.  Results given as mean ± standard deviation (n=4). Please note that the x-338 
axis is not linear. 339 
 340 
3.3 Effect of internal phase volume on the porosity and release of GOS from PLGA 341 
microcapsules 342 
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After the initial study, attempts were made to increase the rate of release of GOS from these 343 
materials in order to try and recover greater amounts of GOS from these devices during GI 344 
passage. Work conducted by Schlicher et al (Schlicher et al., 1997) and Mahboubian et al 345 
(Mahboubian et al., 2010) found that increasing the volume of the internal phase in WOW 346 
prepared PLGA microcapsules with increased their apparent surface porosity. It is believed 347 
that this increase in surface porosity results in an increased rate of drug release from the 348 
microcapsules. The internal phase volume was increased from 0.5 mL to 1.0 and 2.0 mL, and 349 
the microcapsules’ apparent porosity was examined using SEM (Figure 3), revealing a great 350 
increase in porosity as the internal phase volume was increased to 2.0 mL. This was consistent 351 
with the literature available and was attributed to the increased probability of finding droplets 352 
of internal phase close to the boundary of the capsules during the microcapsule formation 353 
process (Herrmann and Bodmeier, 1995). This work by Herrmann and Bodmeier (Herrmann 354 
and Bodmeier, 1995) also raises the possibility of the thinning of the PLGA crust in higher 355 
internal phase volume microcapsules due to the initial enlargement of emulsion droplets. 356 
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 357 
Figure 3: SEM images showing the morphology of microcapsules prepared with 0.5 mL (a,b), 358 
1.0 mL (c,d) and 2.0 mL (e,f) internal phase volume (top to bottom). 359 
 360 
In vitro GI transit was conducted with the microcapsules prepared with 1.0 and 2.0 mL internal 361 
phase volume in order to establish whether this increase in internal phase would be met with 362 
a b
c d
e f
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a change in the release profile. These experiments (Figure 4) reveal that increasing the internal 363 
phase from 0.5 to 1.0 mL led to a slight increase in the percentage of GOS released over the 364 
first 6 hours of testing, from 24.40 ± 5.21 % to 36.11 ± 2.33 % (the latter correlating to 55.00 ± 365 
3.52 mg GOS/g particles). This time period corresponds to the first phase of release outlined 366 
above and theoretically corresponds to stomach and small intestine transit time, and a portion 367 
of the distal colon. Increasing the internal phase volume further resulted in a very large 368 
reduction in the amount of GOS released during this phase, with only 10.30 ± 1.13 % GOS 369 
released. As this release does not take into account the encapsulation efficiency of the system, 370 
this data is also a reflection of the encapsulation efficiency of the system. The high porosity of 371 
the microcapsules seen in Fig 3e and f has presumably lead to a low encapsulation efficiency 372 
of the GOS in this case, which is reflected in the low concentration seen in the release data. 373 
The microcapsules containing 1.0 mL internal phase were taken forward for further analysis 374 
due to the slightly improved release profile and higher loading obtained. Direct measurement 375 
of the encapsulation efficiencies of the microencapsulation system was challenging, so, the 376 
data has been presented as the percentage of GOS released, relative to that put into the 377 
system. The encapsulation efficiency of the 1.0 mL system was estimated to be 90 % by 378 
measuring the GOS present in the continuous alginate phase, i.e. the GOS not encapsulated 379 
into the microparticles. The encapsulation efficiency was calculated using the formula: 380 
encapsulation efficiency = 100-100(GOS present in continuous phase/quantity of GOS added).   381 
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 382 
Figure 4: Effect of internal phase volume on the release of GOS from GOS/PLGA 383 
microcapsules. Data given as mean and standard deviation (n = 3). The position in the GI tract 384 
simulated is overlayed.  Please note that the x-axis is not linear. 385 
3.4 Production and evaluation of PLGA/alginate multiparticulates 386 
The next step in the production of the intended synbiotic microcapsules was the incorporation 387 
of the 1.0 mL internal phase PLGA microcapsules into alginate gels. This can be simply 388 
achieved by the co-extrusion of alginate and the PLGA microcapsules into CaCl2. Alginate-PLGA 389 
microcapsules were produced by this method, dried by fluid-bed drying and their structure 390 
observed using SEM (Figure 5). The SEM observation of fluid-bed dried alginate/PLGA 391 
multiparticulates revealed that the outer surface appeared to be highly occupied by PLGA 392 
particles. The internal structure was dense and showed clear evidence of PLGA microcapsules 393 
present within the matrix. It was also observed that the product was of a greater sphericity 394 
than the alginate microcapsules produced in a previous publication (Cook et al., 2011). This 395 
was most likely due to the PLGA microcapsules acting as a ‘filler’ in a similar manner to starch, 396 
reported widely in the literature (Chan et al.). 397 
0
5
10
15
20
25
30
35
40
45
0 1 2 4 6 24 72 120
%
 G
O
S 
re
le
as
e
Incubation time (h)
1.0 mL internal
phase
2.0 mL internal
phase
20 
 
 398 
Figure 5: Fluid-bed dried alginate/PLGA multiparticulates observed using SEM. The external 399 
surface is shown at 50x (a), 500x (b) and 1000x (c) magnification. The internal structure is then 400 
shown at 50x (d), 500x (e) and 1000x (f) magnification 401 
In order to establish the release profile of GOS from the alginate/PLGA multiparticulates, the 402 
same in vitro method was used as for the PLGA particles alone. However, the purification 403 
process used previously was not applicable to solutions containing alginate as the 404 
polysaccharide is incompatible with the required eluent. A new method of purification was 405 
established, and it was found that the addition of a stoichiometric amount of calcium chloride 406 
led to the cross-linking of alginate and formation of an insoluble calcium phosphate. Both of 407 
these contaminants could be removed from solution by microfiltration. The formation of 408 
insoluble calcium phosphate was pH dependent; all samples were adjusted to pH 7.0 with a 409 
known volume of 1 M NaOH, so that the final data could be adjusted to take this volume 410 
change, and the volume of calcium chloride added, into account. This method led to a 411 
recovery of 95.3 ± 1.7 % of GOS when a solution of 2 mg/mL BiMuno™ in simulated intestinal 412 
solution (pH 7.0) with 1 % alginate added was purified. 413 
500 μm 50 μm 20 μm
20 μm20 μm400 μm
a b c
d e f
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To establish the effect of the polysaccharides alone, alginate and alginate-chitosan 414 
microcapsules were loaded with GOS and fluid-bed dried before being put through the 415 
simulated GI passage. The rate of GOS release with time was established using the previously 416 
described method of purification (Fig. 3s, Supplementary Information). The data shown allows 417 
two conclusions to be drawn; the encapsulation efficiency (i.e. the percentage of GOS added 418 
to the emulsion that was present in the final product) of GOS is very low and there was only a 419 
small control of release. This means that alginate and alginate-chitosan could not be used 420 
individually to deliver GOS in large amounts. The low encapsulation efficiency is 421 
understandable due to the length of time these materials are left to harden in calcium 422 
chloride, during which there will be diffusion of GOS from the matrix. As the cross-linking 423 
density of the alginate matrix increases with time, the diffusion of GOS out of the alginate 424 
would be most pronounced during the early stages of gelation, when the ‘porosity’ of the 425 
material is very high due to the low cross-linking density. Comparison of alginate and alginate-426 
chitosan does not yield any apparent differences in the rate of release of GOS, but it does 427 
appear that GOS loading into alginate microcapsules is higher, which would be a result of 428 
further diffusion of GOS out of the particles during the chitosan coating process. It should be 429 
noted, however, that the errors associated with the data make comparison of alginate to 430 
alginate-chitosan difficult. The encapsulation efficiencies were calculated, using the final 431 
reading of this experiment as the materials had completely dissolved, as 0.7 ± 0.2 % and 0.5 ± 432 
0.2 % for alginate and alginate-chitosan, respectively. 433 
GOS/PLGA multiparticulates were put through the in vitro GI model previously described and 434 
GOS release evaluated using the new purification method.  The results in Figure 6 show that 435 
the level of release of GOS was not greatly affected by further encapsulation into alginate or 436 
alginate-chitosan, but there did appear to be a slight delay of release. In the case of the 437 
alginate-chitosan system the apparent change in release profile was greater, with some 438 
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release appearing to occur between 12-24 h, but the change was within error so conclusions 439 
are difficult to be drawn. Another, slightly unusual advantage of encapsulating the PLGA 440 
microcapsules was also observed. Prior to alginate encapsulation the PLGA microcapsules 441 
floated in solution, as seen in the in vitro studies for the PLGA capsules alone. The 442 
microcapsules would float for several hours before sinking, presumably due to sufficient water 443 
uptake. After encapsulation, the formulation would sink, and by dissolution of the alginate the 444 
PLGA microcapsules had apparently taken up sufficient water to not float. Whilst this seems 445 
initially trivial, in vivo this would result in the retention of the formulation in the stomach, as is 446 
the intention of floating delivery devices (Kawashima et al., 1992), so that the PLGA 447 
microcapsules would release a larger fraction of their load into the stomach.  448 
 449 
Figure 6: Release of GOS from PLGA/alginate (blue diamonds) and PLGA/alginate-chitosan 450 
(red-squares) multiparticulates during simulated GI passage. The release of GOS from PLGA 451 
microcapsules containing 1 mL internal phase overlaid (green triangles). Data given as mean ± 452 
standard deviation (n=3). 453 
0
5
10
15
20
25
30
35
40
45
0 5 10 15 20 25 30
%
 G
O
S 
re
le
as
e
Time (h)
0
5
10
15
20
25
30
35
40
45
0 5 10 15 2 2 3
%
 G
O
S 
re
le
as
e
Time (h)
p
H
 2
.0
p
H
 6
.0
p
H
 7
.2
p
H
 5
.5
23 
 
3.5 Incorporation of B.breve into PLGA/alginate multiparticulates 454 
Finally, to ensure that the inclusion of PLGA microcapsules did not adversely affect the ability 455 
of the alginate microcapsules to protect the cells, B. breve was included into the 456 
multiparticulate alginate matrices in which the GOS/PLGA microcapsules were also 457 
incorporated. These microcapsules were coated with chitosan in order to evaluate the effect 458 
of coating on these materials. Coating with chitosan has previously shown efficacy in 459 
improving protection from gastric acid (Doherty et al., 2012a).  This system was then run 460 
through the simulated GI passage described previously, with cell counts taken from solution. 461 
This should give an idea of both the number of cells surviving in gastric solution, and the rate 462 
of release of cells from these materials. Results displayed in Figure 7, show higher cell 463 
numbers surviving in the chitosan coated multiparticulate system relative to that predicted by 464 
cell survival after encapsulation in chitosan-coated alginate microcapsules without GOS/PLGA. 465 
It has been found that after encapsulation in alginate-chitosan and fluid-bed drying, 6.6 ± 0.5 466 
log CFU/mL cells of B.breve survived 1 h in simulated gastric solution (Cook et al., 2011). The 467 
data in Figure 7 suggests that up to 8.0 ± 0.3 log CFU/mL cells survived when GOS/PLGA was 468 
included into the formulation, which was statistically different by T-testing (p<0.001). Without 469 
encapsulation, it is known that B.breve survives for less than 1 h in gastric solution (Cook et al., 470 
2011). One possible explanation for the increase in the number viable cells found after 471 
exposure to gastric conditions could be the large number of hydrophobic PLGA microcapsules 472 
found on the surface of the alginate matrix. This could act as a hydrophobic coat, reducing the 473 
water-permeability of the capsules. The particles on the surface could also simply reduce the 474 
surface area of the permeable alginate capsules, thereby slowing the rate of acid diffusion into 475 
the matrix. It is also possible that there is some influence from the encapsulated GOS, 476 
stimulating the growth of cells, but this was thought less likely due to the absence of other 477 
nutrients needed to start cell division. 478 
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 479 
Figure 7: Release of viable B. breve from PLGA/alginate multiparticulates with a single layer of 480 
chitosan in simulated GI conditions, relative to the survival predicted by chitosan-coated 481 
alginate microcapsules. Survival is predicted based on alginate-chitosan systems without 482 
PLGA/GOS microcapsules incorporated.  Limit of detection: 3 log(CFU)/mL. Data given as mean 483 
and standard deviation (n=3). Please note that the x-axis is not linear. 484 
 485 
4.0 Concluding remarks 486 
GOS was successfully encapsulated into hollow PLGA microcapsules. These microcapsules 487 
were able to control the release of GOS, giving a triphasic release profile during in vitro GI 488 
conditions in which around 25 % of the GOS initially added was released over 6 h. In vivo this 489 
timescale should correlate approximately to gastric transit, small intestinal transit and early 490 
large intestinal transit. The porosity of these microcapsules could be varied by altering the 491 
internal phase volume of the microcapsules, but did not affect the rate of release to the 492 
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degree needed to move to a single-phasic release profile. From the volumes used, the largest 493 
quantity of GOS delivered in the first phase of release was 36 %, achieved with 1 mL internal 494 
phase volume. It is possible that in future the release and drug loading of these particles could 495 
be optimised by further examination of the processing parameters and PLGA/GOS 496 
concentrations. The incorporation of GOS/PLGA microcapsules into alginate and chitosan-497 
coated alginate microcapsules gave similar results to the GOS/PLGA microcapsules alone, with 498 
a small extension of release seen in the chitosan coated capsules. Incorporation into alginate 499 
systems halted the floatation of the formulation, which would alter the distribution of the GOS 500 
in vivo. Expanding this system to also include B. breve resulted in a higher survival of cells 501 
when exposed to simulated gastric solution, which is believed to be, in part, due to the 502 
increased hydrophobicity of the materials after the incorporation of PLGA microcapsules. 503 
  504 
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 633 
Figure 1s. GOS separation using ion-exchange chromatography. Peaks, from left to right: 634 
penta-, tetra-, tri-, di- and mono- saccharides. RID: Refractive Index Detection 635 
 636 
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 638 
Figure 2s.In vitro GI passage used in GOS release studies 639 
 640 
Region simulated  pH  Exposure time (h)  
Stomach  2.0  0-1  
Proximal small intestine  6.0  1-2  
Distal small intestine  7.2  2-4  
Large intestine  5.5  4 onwards  
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 642 
Figure 3s. Release of GOS from alginate and alginate-chitosan capsules 643 
 644 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4 5
%
 G
O
S 
re
le
as
e
Incubation time (h)
pH:2.0       6.0        7.2
